Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries

Valneva and and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva‚Äôs single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs).

Read more